Radius announces positive top-line results from completed ACTIVExtend study for TYMLOS(TM)
Radius Health announced positive top-line results from the completed 24 month ACTIVExtend trial, which met all of its primary and secondary endpoints. Patients who completed 18 months of TYMLOS (abaloparatide) injections were transitioned to receive 24 additional months of open-label alendronate. May 24, 2017